NCT02278185View on ClinicalTrials.gov

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

April 10, 2019

Study Completion Date

July 18, 2024

Conditions

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage III Prostate CancerStage IV Prostate Cancer

Interventions

DRUG

Enzalutamide

Given PO

DRUG

leuprolide acetate

Given SC or IM

DRUG

goserelin acetate

Given SC or IM

DRUG

histrelin acetate

Given SC or IM

DRUG

triptorelin

Given SC or IM

DRUG

degarelix

Given SC or IM

Trial Locations (2)

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

80524

University of Colorado Health - Poudre Valley Hospital, Fort Collins

All Listed Sponsors

lead

University of Colorado, Denver

OTHER

NCT02278185 - Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter